Omkar Pharmachem Ltd

As of 15-Oct, Omkar Pharmachem Ltd is currently priced at Rs 28.05, reflecting a 4.78% increase and outperforming its sector. Despite this rise, there is a notable decline in investor participation, with delivery volume down 93.58% from the 5-day average.

As of 29-Sep, Omkar Pharmachem Ltd's stock price is Rs. 25.50, down 4.96% and hitting a new 52-week low. The stock has underperformed its sector and shows negative investor sentiment, indicated by erratic trading and being below key moving averages.

Omkar Pharmachem has shown minimal financial activity, with net sales at zero since Mar'18, but has stabilized other operating income at 0.54 Cr since Mar'22. While profit metrics have gradually improved, the company still carries negative reserves, though the deficit has decreased from -1.42 Cr in Mar'21 to -0.65 Cr in Mar'25.

As of August 12, 2025, Omkar Pharmachem is considered very expensive and overvalued, with a PE ratio of 25.90 and a PEG ratio of 4.92, indicating its growth prospects do not justify its current price despite a strong historical return of 323.06%.

As of May 12, 2025, Omkar Pharmachem shows a mildly bullish trend, supported by daily moving averages and Bollinger Bands, though caution is advised due to bearish signals from the weekly and monthly MACD and RSI.

As of May 12, 2025, Omkar Pharmachem shows a mildly bullish trend, supported by daily moving averages and Bollinger Bands, though caution is advised due to bearish signals from the weekly and monthly MACD and RSI.

As of May 12, 2025, Omkar Pharmachem is considered very expensive and overvalued, with a PE ratio of 27.97 and higher valuation metrics than peers like Cipla and Dr. Reddy's Labs, despite a recent 23.14% return that has begun to decline relative to the Sensex.

Omkar Pharmachem has shown minimal financial activity, with net sales at zero from March 2018 to March 2025, while total operating income increased slightly to Rs 0.54 crore. Operating profits peaked at Rs 0.31 crore in March 2023, with profit before tax reaching Rs 0.27 crore in March 2025, indicating a stable but stagnant financial position.

As of Jun 06, Omkar Pharmachem Ltd has a market capitalization of 28.00 Cr, classifying it as a Micro Cap company, with total assets of 9.49 Cr and shareholder's funds of 9.23 Cr as of Mar'24. The company reported net sales of 0.00 Cr and a net profit of 0.20 Cr over the latest four quarters.

The top shareholders of Omkar Pharmachem include promoter Shah Kirtikumar Laxmichand with 0.02% and public shareholder Kuldeep Singh with 3.72%. Individual investors hold a significant 98.36% of the shares, with no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

Omkar Pharmachem Ltd is a micro-cap company focused on pharmaceuticals and chemical products, primarily providing support services. As of March 2025, it reported a net profit of 0 Cr and has a market cap of Rs 28 Cr.

As of March 2018, the management team of Omkar Pharmachem includes Anurag Sharma (Managing Director), Parminder Sharma (Non Executive Director), Mamta Pachori (Non Executive Independent Director), Janak Raj (Non Executive Independent Director), and Pankaj Singh (Company Secretary & Compliance Officer).

Omkar Pharmachem's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Hind.Fluoro Carb, Pentokey Organy, Jayshree Chem., and Sreechem Resins. Their management risks range from excellent to below average, with India Glycols showing the highest 1-year return at 150.39% and Omkar Pharmachem at 26.92%.